Leukemogenesis
The pathogenesis of leukemia may be explained by two classes of alterations of oncogenic genes as a result of chromosomal aberrations. Class I mutations confers a proliferative and/or survival advantage to the cells. The current list of known leukemogenic class I mutations consists of more than 10 different protein tyrosine kinases (PTK) that undergo constitutive activation either by being fused to different N-terminal partner proteins providing an oligomerization domain, or by activating mutations such as point mutations in their kinase domain or internal tandem repeats (length mutations) in the juxtamembrane domain (Flt3, Kit). Most of these alterations are associated with chronic myeloproliferative disorders such as chronic myeloid leukemia/chronic myelomonocytic leukemia (CML/CMML) or Philadelphia negative myeloproliferative disorders, except activating mutations of Flt3 and Kit which are found almost exclusively in acute leukemia. Flt3 ITD (internal tandem duplication) mutants constitutively activate MAPK, AKT and STAT5, leading to Pim-1 activation and Bcl-xL (B-cell lymphoma) hyperexpression (Minami et al., 2003; Kim et al., 2005) . Extracellular c-Kit mutations resulted in c-Kit receptor 
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Signal Transduction Pathways (STP)
Signal transduction is the primary means by which eukaryotic cells respond to external signals from their environment and coordinate complex cellular changes. Extracellular signal is transduced into the cell through ligand-receptor binding, followed by the activation of intracellular signaling pathways that involve a series of protein phosphorylation and dephosphorylation, protein-protein interaction, and protein-small molecules interaction (Liu and Zhou, 2004) . Cytokines interact with cell-surface receptors initiating signaling cascades that promote cell growth and division, while inhibiting the pathways of apoptotic cell death. The JAK/STAT, Raf/ MEK/ERK and PI3K/Akt signaling pathways are activated by a variety of cytokines that function to potentiate or inhibit hematopoiesis. These include IL (interleukin)-3, IL-7, SCF (stem cell factor), G (granulocyte)-CSF, type I interferons (IFN) and TGF-(transforming growth factor)-beta (Steelman et al., 2004 
Protein kinase B (Akt)
Akt is a 57-kDa serine/threonine protein kinase central to cell signaling downstream of growth factors, cytokines, and other cellular stimuli. Activated Akt was originally isolated from cells of the leukemia and lymphoma prone AKR strain of mice (Staal, 1987) . It comprises three highly conserved isoforms: Akt1/ , Akt2/ , and Akt3/ which are functionally different (Staal, 1987 3 (GSK3 ). Each of these substrates has a key role in the regulation of cell survival and proliferation, either directly or through an intermediary. The antiapoptotic effects of Akt occur through its phosphorylation of a wide variety of targets. The first antiapoptotic target identified was Bad, a member of the Bcl-2 family. Phosphorylation of Bad at S136 by Akt allows phosphorylated Bad to interact with 14-3-3 proteins, promoting cell survival (Datta et al., 1997; Andreeff et al., 1999) . Interaction of Bad with 14-3-3 proteins inhibits the ability of Bad to interact with Bcl-2 and Bcl-xL. This allows Bcl-xL to bind to proapoptotic Bax molecules and prevent the formation of proapoptotic Bax homodimers. However, Bad is also phosphorylated on different sites by members of the Raf/MEK/ERK (S112) and PKA (S112, S155) pathways. In human cells, Akt phosphorylates and inactivates caspase-9. Overexpression of Akt inhibits cytochrome c-induced activation of caspase-9 (Cardone et al., 1998) . Phosphorylation of the Foxo family of transcription factors is also attributed to Akt (Biggs et al 1999); Brunet et al., 1999; Rena et al., 1999; Tang et al., 1999) .This phosphorylation results in forkhead transcription factors translocation to the cytoplasm, thus inhibiting transcription of pro-apoptotic genes such as FasL (Brunet et al., 1999) . Akt activates transcription of antiapoptotic genes through phosphorylation of IKK and regulation of nuclear factor-kappa B (NF-kB) (Ozes et al., 1999) . Akt also promotes cell survival and cell cycle progression by its ability to phosphorylate MDM2 and GSK-3 (Fukumoto et al., 2001; Zhou et al., 2001) . Once phosphorylated by Akt, MDM2 translocates to the nucleus and interacts with p300. p300 dissociates from p19ARF, resulting in the degradation of p53 and cell cycle progression. Akt phosphorylates GSK-3, inhibiting its activity. The decreased GSK-3 activity increases stability ofcatenin and enhances its association with lymphoid enhancer factor/T cell factor (LEF/TCF) (Fukumoto et al., 2001) . Thecatenin-LEF/TCF complex increases transcription of proteins such as cyclin D1 and c-myc, promoting cell cycle progression (Fukumoto et al., 2001) . Clearly, Akt can affect both cell cycle progression and apoptosis (reviewed in Steelman et al., 2004) . MTORC1 is a critical regulator of translation initiation and ribosome biogenesis and plays an evolutionarily conserved role in cell growth control (Wullschleger et al., 2006) . The enhanced sensitivity of cancer cells and mouse tumor models exhibiting oncogenic activation of the PI3K-Akt pathway to mTORC1 inhibitors, such as rapamycin, illustrates the importance of mTORC1 activation downstream of Akt (Sabatini, 2006) . One of the bestconserved functions of Akt is its role in promoting cell growth (i.e., an increase in cell mass).
The predominant mechanism appears to be through activation of mTOR complex 1 (mTORC1 or the mTOR-raptor complex), which is regulated by both nutrients and growth factor signaling. mTORC1 signaling integrates environmental clues (growth factors, hormones, nutrients, stressors) and information from the cell metabolic status. Thus, mTORC1 controls anabolic processes for promoting protein synthesis and cell growth transcription factor activity. JAKs are a family of large tyrosine kinases, having molecular weights in the range of 120-140 kDa (1130-1142 aa). Four JAKs (JAK1, JAK2, JAK3 and Tyk2) have been identified in mammals. JAK3 expression is limited to hematopoietic cells (Steelman et al., 2004) . The STAT gene family consists of seven proteins (STAT1,STAT2, STAT3, STAT4, STAT5a, STAT5b and STAT6). Upregulation of STAT3 is detected with high frequency inhuman cancer. STAT3 is activated not only by cytokine receptors, such as the receptor for the IL-6 family cytokines, but also growth receptor tyrosine kinases, such as the EGFR family including Her2/Neu, and non-receptor tyrosine kinases such as Src and Abl (Turkson et al., 1998) , and is also activated in response to stimulation of G-protein-coupled receptors (GPCR) (Pelletier et al., 2003) . Classically, the receptor stimulation by ligand induces STAT3 binding to phosphotyrosine residues of receptors through its SH2 domain and its phosphorylation on a critical tyr705 residue by the receptor itself, or by associated Janus kinase (JAK, Jak1-3, Tyk2) or Src family tyrosine kinases (Yu et al., 2004) . These interact with NF-kB through multiple ankyrin repeats and as a result inhibit its DNA binding activity. Two NF-kB activation pathways exist; the first is normally triggered in response to infections or exposure to pro-inflammatorycytokines that activate the IkB kinase (IKK) complex leading to phosphorylation-induced IkB degradation, the other pathway leads to selective activation of p52: RelB dimers. This pathway is triggered by certain membersof the tumor necrosis factor (TNF)cytokine family through selective activation of IKKa by the upstream kinase, NF-kappa B-inducing kinase (NIK).In response to many stimuli such as inflammatorycytokines, bacterial lipopolysaccharide, phorbol esters, viral infection or stress, IkB are phosphorylated on two critical serine residues (Senftleben et al., 2001).
Fig. 1. Signal transduction pathways (refer text for details)
This modification triggers IkB ubiquitination and destruction via the 26Sproteasome degradation machinery. As a consequence, NF-kBis freed to enter the nucleus and regulate transcription of over 150 genes encoding cell adhesion molecules, cytokines, growth factors, components of the immune systems and anti-apoptotic genes such as FLIP (FLICE inhibitory protein), cIAPs (inhibitor of apoptosis), Bcl-2 and Bcl-xL (Aggarwall, 2004) . It is also implicated in the regulation of cell proliferation by controlling D-type cyclins (Takebayashi et al., 2003) .
The three main signaling pathways are kept in check by naturally occurring inhibitors or tumor suppressor proteins. For example, the JAK/STAT pathway has the SOCS/CIS family of proteins, which serve to limit its effects by a negative feedback pathway. The Raf/MEK/ERK pathway can be negatively regulated by the PI3K/Akt cascade as well as the MKP1 phosphatase, which inactivates phosphorylated ERK. The PI3K/Akt pathway has the PTEN and SHIP phosphatases, which serve to fine-tune its antiapoptotic effects (reviewed in Steelman et al., 2004).
Aberrant STP and drug resistance in AML
Genetic events that give rise to leukemic transformation occur through activation of components of receptor tyrosine kinase (RTK) signaling pathways (Liu and Zhou, 2004 ). These include fusion proteins or gene mutations such as seen with activated TEL-JAK, STAT5A and BCR-ABL. Transforming activity of oncogenic PTK is mediated by parallel activation of several downstream signaling pathways. Final downstream mediators of this complex signaling network are phosphoproteins that translocate to the nucleus and act as transcriptional regulators activating a distinct group of target genes. The oncogenic activity of a given PTK is mediated by several signaling pathways including JAK/STAT, Ras/MAPK, PI3K/AKT, or NF-kB. Oncogenic activity severs dependence of transformed cell on external stimulation for survival. TEL-JAK fusion proteins contain the oligomerization domain of TEL and the tyrosine kinase domains of JAK1, JAK2, JAK3, or TYK2. These efficiently substitute for the survival and mitogenic signals controlled by IL-3, without concomitant activation of the IL-3 receptor. STAT5 are constitutively active in TEL-JAK2-and TEL-JAK1-expressing cells (Lacronique et al., 2000) . The BCR-ABL oncogene produces an activated tyrosine kinase fusion protein and gain independence from IL-3 for cell growth (Mandanas et al., 1992) . Activated forms of Ras, Raf, MEK, PI3K and Akt however, show significant differences in the ability to abrogate cytokine dependence (Steelman et al., 2004) . TEL/JAK2 isoforms, depending on the location of the breakpoints in the JAK2 gene, have been described in acute lymphoblastic leukemia of the B-cell type and atypical CML (Lacronique et al., 1997) . Somatically acquired JAK2 mutation (V617F) was detected in 472/944 (50%) of patients with Ph-negative chronic myeloproliferative disorders [including polycythemia vera (PV), idiopathic myelofibrosis (IMF) and essential thrombocytosis (ET)] with predominance in PV (66%) followed by IMF (42%) and ET (26%) (Jones et al., 2005) . Recent investigation of novel mutations in JAK2 revealed a higher incidence, ~99% and 55% in PV and ET, respectively (Tefferi, 2010) . Flt-3 mediates its proliferative and antiapoptotic effects through several signaling pathways including the STAT5, Ras/MAPK and PI3K/AKT pathways. Overexpression of Flt-3 was detected in 73% of AML and 78% of ALL patients (Nakao et al., 1996) . Flt-3 length mutations (internal tandem duplications (ITD) in the juxtamembrane domain) (Nakao et al., 1996) , is observed in more than 20% of adult and more than 10% of pediatric AML patients harbor an Flt-3-ITD (reviewed in Testa et al., 2007) . In general, patients with mutant FLT3 show higher cell counts and decreased overall survival. Absence of the wild-type allele in patients with Flt-3-ITD predicted poor prognosis in 82 adult de novo AML cases with otherwise normal cytogenetics who received uniform high-dose therapy. Of the the 23 (28%) patients with Flt3-ITD, disease-free survival (DFS) was inferior (P = 0.03), yet overall survival (OS) was not different (P = 0.14) (Whitman et al., 2001) . In cytogenetic normal AML patients aged > 60 years treated on Cancer and Leukemia Group B frontline trials, FLT3-ITD remained associated with shorter disease-free survival (P < .001; hazard ratio 2.10) and overall survival (P < .001; hazard Ratio 1.97) in multivariable analyses (Whitman et al., 2010) . Flt3 kinase domain point mutants is mutated in about 35% of AML (Stirewalt et al., 2003) . In a study of 481 patients, FLT3 mutation did not have an impact on event-free survival (EFS) in patients with CBF-AML (P = .84) and poor-risk AML (P = .37). However, while event-free survival was worse in the FLT3-internal tandem duplication (ITD) group (20 weeks vs 41 weeks; P < .00,001) this was not observed for the FLT3-tyrosine kinase domain (TKD) point mutation group ( From 50% to 80% of patients with AML display Akt phosphorylated on either Thr308 or Ser473 (or both) (Xu et al., 2003; Min et al., 2003) . Univariate analysis of 146 AML patients revealed those with low levels of pAKT had somewhat better CR rates (60% versus 50%; P=0.21), longer median CR durations (71 versus 32 weeks; P=0. 13) , and statistically significant longer median survival times (59 versus 30 weeks; P=0.02) compared with those with high levels of pAKT. In another study, single analysis of Akt phosphorylated at threonine 308 (Thr308) and serine 473 (Ser473) showed AktThr308(high) patients had significantly shorter overall survival (11 vs 47 months; P=0.01), event-free survival (9 vs 26 months; P=0.005) and relapse-free survival (10 months vs not reached; P=0.02) than Thr308(low) patients. This was not observed for Akt Ser473 (Gallay et al., 2009 ). Poor prognosis of AML patients with elevated PI3K/Akt/mTOR signaling could be also related to the fact that this pathway controls the expression of the membrane ATP binding cassette (ABC) transporter, multidrug resistance-associated protein 1, associated with a lower survival rate (Tazzari et al., 2007; Schaich et al., 2005) . Nevertheless, a more recent report has highlighted that constitutive activation of PI3K/Akt/mTOR signaling could be a favourable prognostic factor in de novo cases of AML. One hypothesis for the lower relapse rate in patients with enhanced PI3K/Akt/mTOR signaling is that it could drive immature leukemic cells (LSCs and CFU-L) into S phase, thus rendering them more susceptible to polychemotherapy (Tamburini et al., 2005) The AKT pathway was among the signaling cascades whose simultaneous activation with other pathways, such as PKC and ERK, was found to confer a poor prognosis in AML (Altman et al., 2011) . Eventhough often mutated in human cancer, MMAC1/PTEN gene are infrequent as genetic aberrations in myeloid leukaemia (Aggerholm et al., 2000) NF-kB has been found to be activated in CD34+/CD38-blast cells derived from patients with de novo AML (Guzman et al., 2001; Baumgartner et al., 2002) . Leukemic stem cells residing in this population are quiescent or slowly cycling and therefore less sensitive to chemotherapy. They are therefore likely to be responsible for disease relapse and represent the target for future innovative therapies (Bonnett et al.,1997; Lowenberg et al., 1999; Jordan, 2002) . Activation of NF-kB in leukemia patients has been well documented though NF-kB activation is not uniform among AML patients. Forty percent of AML patients evaluated presented with increased NF-kB DNA binding activity. These patients are characterized by increased white cell counts at diagnosis and increased blast percentages in the bone marrow suggesting a link between NF-kB and cell proliferation. In particular, cyclin D1, whose expression is regulated by NF-kB. Alternatively, NF-kB action could be due to the induction of genes coding for AML growth factors such as GM-CSF or granulocyte colony-stimulating factor (G-CSF) (Cilloni et al., 2007) . The majority of LSCs are quiescent and insensitive to traditional chemotherapeutic drugs. This latter feature explains, at least in part, the difficulties in eradicating this cell population by conventional polychemotherapy. Thus, novel therapeutic strategies for AML eradication should also target LSCs (Misaghian et al., 2009) 
Conclusion
Expression of STP proteins is heterogenous and of prognostic value in AML (Kornblau et al., 2009 ). These signaling pathways in AML may in the future help rationally select targeted therapies in individual patients (Foran, 2010). While current classification schemes have prognostic relevance they generally do not alter therapeutic recommendations. As knowledge of mutated genes in cancersim proves, our ability to treat patients afflicted with certain diseases will increase substantially. The genetic mutation may affect multiple signal transduction pathways. Targeting multiple pathways may be more efficacious as this approach may suppress or eliminate tumor growth at lower concentrations of the drugs than that required to inhibit growth by targeting a single pathway (Steelmanet al., 2004) . The heterogeneity in AML continues to elude the best methods to characterize them. Genome and proteome-wide analysis has further revealed complexity in the makeup of the leukemic cell. The rapid advancement in targeted therapies implied the urgent need for alternative therapy and the readiness of the community to embrace it. Nevertheless so far, combinatorial medicine still holds out as the best option for successful treatment. If targeted therapies remain the way forward it will eventually bank deeply on the ability to identify molecular signatures in the individual leading to the establishment of personalized medicine. Novel array technologies enabled the analysis of numerous features at the level of DNA for gene copy number variation, mutations, methylation in addition to mRNA transcription and regulatory microRNA. Emerging technologies to assess protein expression and phosphorylation levels within cells e.g. cytokine and chemokine arrays to assess external forces acting on leukemic cells and phosphoproteins in apoptosis, cell-cycle, and signaltransduction pathways, are highly needed. Protein expression and posttranslational modifications, either alone or in concert with other profiling approaches, could provide independent or complementary information not captured by transcriptional profiles. Protein signature groups, with prognostic information distinct from cytogenetics may reveal underlying similarities indistinguishable by cytogenetics (Kornblau et al., 2009 ). Quantitative flow cytometry appears well suited for identifying predictive markers in AML patients because it offers obvious advantages over other techniques (western blot, for example), including rapidness, a much lower number of cells required to perform the assay, and the possibility of identifying different subclones in the leukemic population by coimmunostaining with multiple antibodies to surface antigens (Martelli et al., 2010) . The mechanisms in leukemogenesis, drug resistance and relapse remain an area of much research. From cell biology to cytogenetics to molecular defects to signaling pathways, all have contributed to a better understanding of the cancer. New knowledge in epigenetics and microRNA remain to be elucidated. Identification of mcl-1 as a BCR/ABL dependent target in chronic myeloid
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